Aldeyra The (ALDX) - Total Assets
Based on the latest financial reports, Aldeyra The (ALDX) holds total assets worth $77.80 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ALDX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Aldeyra The - Total Assets Trend (2011–2024)
This chart illustrates how Aldeyra The's total assets have evolved over time, based on quarterly financial data. Check Aldeyra The (ALDX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Aldeyra The - Asset Composition Analysis
Current Asset Composition (December 2024)
Aldeyra The's total assets of $77.80 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Aldeyra The's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aldeyra The (ALDX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aldeyra The's current assets represent 99.5% of total assets in 2024, an increase from 98.6% in 2011.
- Cash Position: Cash and equivalents constituted 52.1% of total assets in 2024, down from 96.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aldeyra The Competitors by Total Assets
Key competitors of Aldeyra The based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Aldeyra The - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.72 | 6.80 | 6.69 |
| Quick Ratio | 2.72 | 6.80 | 6.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $48.98 Million | $99.57 Million | $70.65 Million |
Aldeyra The - Advanced Valuation Insights
This section examines the relationship between Aldeyra The's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.76 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | -29.5% |
| Total Assets | $104.61 Million |
| Market Capitalization | $110.10 Million USD |
Valuation Analysis
Above Book Valuation: The market values Aldeyra The's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Aldeyra The's assets decreased by 29.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aldeyra The (2011–2024)
The table below shows the annual total assets of Aldeyra The from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $104.61 Million | -29.48% |
| 2023-12-31 | $148.33 Million | -18.18% |
| 2022-12-31 | $181.29 Million | -22.24% |
| 2021-12-31 | $233.14 Million | +179.70% |
| 2020-12-31 | $83.35 Million | +10.37% |
| 2019-12-31 | $75.52 Million | -20.58% |
| 2018-12-31 | $95.09 Million | +115.26% |
| 2017-12-31 | $44.17 Million | +75.38% |
| 2016-12-31 | $25.19 Million | -10.70% |
| 2015-12-31 | $28.20 Million | +220.98% |
| 2014-12-31 | $8.79 Million | +134.75% |
| 2013-12-31 | $3.74 Million | +89.34% |
| 2012-12-31 | $1.98 Million | +663.61% |
| 2011-12-31 | $258.90K | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more